Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing.
We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss.
The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide.
For more information, please visit www.verdivabio.com.
Company Details
- Employees
- 53
- Address
- London, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://verdivabio.com/
- HQ
- London
Verdiva Bio Questions
Verdiva Bio's website is https://verdivabio.com/
Verdiva Bio's LinkedIn profile is https://www.linkedin.com/company/verdivabio
Verdiva Bio has
53 employees.
View email and phone details for 53
employees at Verdiva Bio.
Verdiva Bio's industry is
Biotechnology Research
Verdiva Bio's top competitors are
Newleos Therapeutics,
Kardigan,
Tenvie Therapeutics,
Aiolos Bio,
Abcuro, Inc,
Aviceda Therapeutics,
Ouro Medicines,
Timberlyne Therapeutics,
Metsera,
Isomorphic Labs.
Verdiva Bio's categories are Biotechnology Research
